EMA Postpones Clinical Trial Transparency Plan Indefinitely

Drug Industry Daily
A A
The European Medicines Agency (EMA) has indefinitely postponed a controversial plan to begin releasing to the public detailed information from clinical study reports contained in new drug applications, the central element to its clinical trial transparency initiative.

To View This Article:

Login

Subscribe To Drug Industry Daily